Activated PI3K/Akt/mTOR signaling drives angiogenesis, cancer cell metabolism, growth, and survival (11), highlighting the potential of therapies that show activity in the CNS and target this oncogenic signaling axis for the treatment of DIPG. Here, AKT1 is linked to cancer.